BRAF V600E Mutations and BAALC Expression in Melanoma
Author Information
Author(s): David Schrama, Gunhild Keller, Roland Houben, Christian G. Ziegler, Claudia S. Vetter-Kauczok, Selma Ugurel, Jürgen C. Becker
Primary Institution: Department of Dermatology, Julius-Maximilians University, Würzburg, Germany
Hypothesis
The study investigates the relationship between BRAFV600E mutations and the expression of BAALC in melanoma cell lines.
Conclusion
BAALC may function as a downstream effector of activating BRAF mutations during melanomagenesis.
Supporting Evidence
- BAALC was up-regulated by an average of 11.45 fold in BRAFV600E mutated cell lines.
- Real-time PCR confirmed the BRAF-activation dependent up-regulation of BAALC in melanoma cell lines.
- The study identified a more than two fold down-regulation of 43 and an increase of 39 gene products in mutated cell lines.
Takeaway
The study found that a gene called BAALC is more active in melanoma cells with a specific mutation, which might help the cancer grow.
Methodology
Microarray gene analysis and real-time PCR were used to compare gene expression in melanoma cell lines with and without BRAFV600E mutations.
Potential Biases
Lab-dependent differences in sample handling and analysis could introduce variability in results.
Limitations
The study used a limited number of cell lines, which may not represent all melanoma cases.
Participant Demographics
The study analyzed human melanoma cell lines, including those with BRAFV600E and RAS mutations.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website